Welcome to our dedicated page for Lantheus Holdings news (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holdings stock.
Lantheus Holdings, Inc. (NASDAQ: LNTH) is a leading radiopharmaceutical-focused company, dedicated to the development, manufacture, and commercialization of innovative diagnostic imaging agents and products. Headquartered in North Billerica, Massachusetts, and with additional offices in Puerto Rico and Canada, Lantheus has been a pivotal player in the medical imaging industry for over 65 years.
The company's primary subsidiary, Lantheus Medical Imaging, Inc. (LMI), specializes in diagnostic imaging solutions primarily for cardiovascular diseases. Key products include the echocardiography contrast agent DEFINITY® Vial, the technetium-based generator TechneLite®, and the inhaled radiopharmaceutical imaging agent Xenon Xe 133 Gas for lung imaging.
Lantheus is organized into three main business units: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostics focuses on products that assist healthcare professionals in detecting and monitoring diseases, particularly in cardiology. Radiopharmaceutical Oncology offers diagnostics and therapeutic solutions that help healthcare providers manage cancer. Through its Strategic Partnerships, Lantheus collaborates to advance precision medicine using biomarkers and digital solutions.
Recent achievements include strategic transactions to enhance their pipeline for neuroendocrine tumors and prostate cancer. Lantheus has partnered with Perspective Therapeutics, which has developed a best-in-class alpha therapy platform, enabling Lantheus to expand its pipeline into promising alpha therapies.
Financially, Lantheus has shown robust performance. The company reported record revenues of $1.3 billion for the full year 2023, marking a 38.6% increase from 2022. This growth was driven by the successful commercialization of innovative products and strategic acquisitions.
In the Radiopharmaceutical Oncology space, the company’s Abbreviated New Drug Application (ANDA) for Lutetium Lu 177 Dotatate has been accepted by the FDA. This product is intended for treating somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Lantheus continues to drive innovation and growth through its robust pipeline and strategic collaborations. Recent leadership changes have positioned the company for its next phase of growth, with Brian Markison taking over as CEO from March 2024, following the successful tenure of Mary Anne Heino.
For ongoing updates and more information, visit their website at www.lantheus.com.
Lantheus Holdings (NASDAQ: LNTH) has entered into a strategic collaboration with POINT Biopharma Global (NASDAQ: PNT) for exclusive worldwide rights to two late-stage radiopharmaceuticals, PNT2002 and PNT2003. Lantheus will pay $260 million upfront, with potential milestone payments reaching approximately $1.8 billion. The collaboration aims to enhance Lantheus’ prostate cancer portfolio and drive long-term revenue growth. Both companies will fund and complete clinical trials, with Lantheus retaining commercialization rights post-FDA approval.
Lantheus Holdings (NASDAQ: LNTH) announced that CFO Bob Marshall will present at the Jefferies London Healthcare Conference on November 16, 2022, at 8:00 a.m. GMT (3 a.m. EST). The live webcast can be accessed on the company's website, with a replay available for 30 days post-presentation. Lantheus has over 65 years of experience in improving patient outcomes through diagnostics, radiotherapeutics, and AI solutions, aimed at helping clinicians Find, Fight, and Follow disease. The company is based in Massachusetts, with additional offices in New Jersey, Canada, and Sweden.
Lantheus reported a remarkable third quarter for 2022, achieving worldwide revenue of $239.3 million, marking a 134.4% increase year-over-year. The company's GAAP net income surged to $61.2 million or $0.86 per fully diluted share, compared to a loss of $13.4 million in the same quarter of 2021. Adjusted fully diluted EPS was $0.99, up from $0.08 a year earlier. With operating cash flow at $93.6 million and free cash flow of $87.5 million, Lantheus also provided positive guidance for Q4 and updated full-year 2022 expectations.
Lantheus Holdings (NASDAQ: LNTH) announced a conference call and webcast for November 3, 2022, at 8:00 a.m. ET to discuss Q3 2022 financial and operating results. The company encourages participants to register online ahead of time to avoid delays. A replay will be available approximately two hours post-event for 30 days. Lantheus, with over 60 years of experience, focuses on improving patient outcomes through diagnostics and AI solutions in healthcare.
Lantheus Holdings (NASDAQ: LNTH) presented AI data at the 2022 EANM Annual Meeting in Barcelona, showcasing the clinical utility of PYLARIFY AI for prostate cancer treatment. Key highlights include a top-rated presentation demonstrating a strong association between automated PSMA scores and PSA response in prostate cancer, indicating that a quantitative PSMA score can effectively assess treatment response. The company also unveiled new adaptive methodologies improving tumor burden quantification in PSMA PET/CT imaging. PYLARIFY AI is FDA-cleared and aims to enhance diagnostic efficiency.
The Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical has met its co-primary endpoints for detecting Coronary Artery Disease (CAD), exceeding 60% in both sensitivity and specificity. The trial demonstrated higher efficacy than SPECT Myocardial Perfusion Imaging, with over 600 patients participating across multiple regions. If approved, [18F]flurpiridaz’s longer half-life could significantly increase patient access to PET MPI, enhancing diagnostic accuracy and patient outcomes, as noted by experts at the ASNC Congress.
GE Healthcare and Lantheus Holdings have announced that their Phase III clinical trial of the investigational radiotracer [18F]flurpiridaz has successfully met co-primary endpoints for detecting Coronary Artery Disease (CAD), exceeding 60% in both sensitivity and specificity. This trial demonstrated superior diagnostic efficacy compared to SPECT Myocardial Perfusion Imaging. With a half-life approximately 12 times longer than existing PET tracers, [18F]flurpiridaz could significantly improve patient access to PET MPI if approved.
NORTH BILLERICA, Mass., Sept. 01, 2022 – Lantheus Holdings (NASDAQ: LNTH) announced that Bob Marshall, CFO, and Paul Blanchfield, COO, will present at the Wells Fargo Healthcare Conference on September 8 at 8:00 a.m. ET. The presentation will focus on the company’s commitment to innovative diagnostics and therapeutics, including artificial intelligence solutions that enhance patient outcomes. A live webcast can be accessed through the Investors section of the company's website, with a replay available for 30 days.
Lantheus Holdings reported $223.7 million in worldwide revenue for Q2 2022, marking a 121.4% increase from Q2 2021. The company achieved a GAAP net income of $43.1 million, or $0.61 per diluted share, compared to a net loss of $26.7 million in the previous year. Adjusted fully diluted EPS increased to $0.89 from $0.11. Net cash provided by operating activities was $72.6 million, with free cash flow at $68.3 million. The company has raised its full-year revenue guidance to between $885 million and $905 million.
Lantheus Holdings, Inc. (NASDAQ: LNTH) has announced it will host a conference call and webcast on August 4, 2022, at 8:00 a.m. ET to discuss its second-quarter 2022 financial and operating results. Interested participants should register in advance to avoid delays. A replay will be available shortly after the event and archived for at least 30 days. Lantheus, with over 60 years of experience, focuses on improving patient outcomes through diagnostics, radiotherapeutics, and AI solutions.
FAQ
What is the current stock price of Lantheus Holdings (LNTH)?
What is the market cap of Lantheus Holdings (LNTH)?
What does Lantheus Holdings, Inc. specialize in?
What are some key products of Lantheus?
Where is Lantheus Holdings headquartered?
What are the core business units of Lantheus?
Who is the current CEO of Lantheus Holdings?
What recent achievements has Lantheus accomplished?
What financial growth did Lantheus achieve in 2023?
What is the significance of DEFINITY® Vial?
What types of diseases does Lantheus focus on in their diagnostics?
How does Lantheus contribute to precision medicine?
